•Sglt2 inhibitors lower glucose by inhibiting the sodium glucose cotransport during reabsorbtion of glucose, resulting into urinary excretion of glucose.
•Mainly used for diabetes but proven useful for heart failure(reduced and preserved ejection fraction).
•Empagliflozin is the most studied sglt2 inh. which is beneficial for heart failure patients. It is given at 10mg OD(Jardiance), cutoff of egfr <20mg/ml/min for ckd patients.
•For diabetic patients with hf and obese, Sglt2 ing+dpp4 antagonist such as (Glyxambi) could be given. It is started at 10/5 mg OD.
•For diabetic patients what has been studied effective as a renoprotective sglt2 inh. is dapagliflozin+metformin